Anthony Davies

Anthony Davies has a diverse range of experience in the biotech industry. Starting in 2002, they worked as an Associate Director of Process Development at Syrrx. From 2004 to 2005, they served as Senior Director of Manufacturing at ZymeQuest. Davies then became Director of Process Development at Serologicals in 2005. Anthony later joined Geron Corporation as VP of Product Development from 2006 to 2012. In 2013, they were Chief Technology Officer at Capricor, Inc., responsible for manufacturing, quality systems, and development of their cell-based therapeutic portfolio. From 2012 to 2015, Davies was a Scientific Advisory Board Member at Park BioVentures LLC. In 2014, they became a member of the Scientific Advisory Board at BioLife Solutions, Inc. The following year, in 2017, they became a Non-Executive Director at TrakCel Ltd. Anthony later founded their own consultancy, Dark Horse Consulting Group Inc., which specializes in cell and gene therapy, mergers and acquisitions, and engaging strategic corporate partners and investors. Currently, they are also a Mentor for the Advanced Therapies Stream at Creative Destruction Lab, a nonprofit organization that supports the growth of science and technology-based companies.

Anthony Davies completed their education with a PhD in Biochemical Engineering from the University of Birmingham, which they pursued from 1986 to 1990. Prior to this, they obtained an MA degree in Natural Sciences with a specialization in Biochemistry from the University of Cambridge between 1983 and 1986. Anthony's earlier education included attending Brighton College from 1972 to 1982. The specific degree obtained and field of study during this time period is not mentioned.